Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134124) titled 'Ustekinumab and low-dose Upadacitinib combination therapy in medically difficult-to-treat patients with Crohn's disease' on Oct. 11.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Department of Gastroenterology, the Tenth People's Hospital of Tongji University
Condition:
Crohn's disease
Recruitment Status: Not Recruiting
Phase: Retrospective study
Date of First Enrollment: 2025-05-05
Target Sample Size: Ustekinumab combined with low dose upadacitinib:84;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=265355
Disclaimer: ...